Skip to main content
CYIENTDLM 864.0500 INR +3.49%
CYIENTDLM · Cyient DLM Limited
864.05 INR +29.10 (+3.49%) At close · Nov 13
Volume · Nov 13 17.4K Avg daily vol (3M) 71.06K
All webcasts

Earnings call · FY2027 Q2

Cyient DLM Limited (CYIENTDLM) Q2 2027 Earnings Call Transcript

Concluded Oct 15, 2026 Audio replay
Oct 15, 2026 1:01:17 96 turns
Period
FY2027 Q2
Runtime
1:01:17
Sources
3 artifacts
Revenue 3.93B INR +26.5% YoY
Diluted EPS 4.28 INR/shares +5.7% YoY
Net income 0 INR
Open full screen Slides 18

Transcript & audio

1:01:17 Audio
Operator

Ladies and gentlemen, good day and welcome to the SCIENT-DLM Limited Q2 FY27 Results Conference Call. As a reminder, all participant clients will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Krishna Bodanapu, non-executive chairman, Scient DLM Limited. Thank you, and over to you, sir.

Krishna Bodanapu Chairman

Thank you very much, Darwin, and good evening, ladies and gentlemen. I am Krishna Bodanapu, non-executive chairman of Scient DLM Limited. It is my pleasure to welcome you to our Q2 FY27 earnings call. And joining me today are our Managing Director and CEO, Mr. Rajendra Velgapudi, and our CFO, Mr. R.M. Subramaniam. Before we begin, I would like to remind you that certain during this call may be forward-looking in nature and are subject to risks and uncertainties. A detailed disclaimer is available in the Investor Update section posted on our website. Let me begin with what I believe is one of the strongest indicators of the underlying momentum in our business. The continuous strength of our order book and sales pipeline. Happy to note that the headline number is that order backlog now stands at 2,813 crores, which there is a pipeline which is in excess of a continuous to pick up during the course of the quarter. We've sustained positive momentum in our order book for six continuous quarters. During Q2, our book-to-bill ratio remained at over 1.6 times, supported by strong order out-in flows from large OEMs. We've also surpassed the record order book achieved in the previous quarter, providing us with strong revenue visibility. This reinforces the confidence our customers continue to place in our quality, delivery, performance, and capabilities. Our execution teams have done a commendable job in fulfilling critical customer requirements despite the continued supply chain shortages, longer lead terms, and geopolitical uncertainties, especially driven by what is happening in the memory market. This has resulted in a revenue growth of more than 26% year-on-year during this quarter, which is broadly in line with our expectations. We're seeing positive growth across all key segments. Aerospace and industrial continues to grow at a faster pace, while defense and medical are gaining momentum. We have also strengthened the sales leadership team recently, bringing in diverse experience and capabilities that will help accelerate our revenue and profit growth agenda. This gives us greater confidence in the execution of our strategy. While Rajendra will elaborate on this further, our strategic direction remains clear, which is to deepen and scale our presence in existing segments while selectively expanding into attractive new growth areas. As we position the business for the next phase of growth, we have continued to invest in our sales organization, strategic capabilities, and the overall foundation to support the next phase of growth. These are deliberate investments. While they have an impact on margins in the near term, we believe that they're important, stronger, and more scalable business. These investments are in two dimensions. One is the investments that we have made in our go-to-market organizations, sales, marketing, etc. And the second, and sorry, that leads to better pipeline, better backlog, and of course, eventually better margin and growth, which we're starting to see. The second investment is in our B2S. Everything is done up front. The IP is co-owned by Sion DLM with our customers, and we have a very long manufacturing responsibility for many, many years. So both are very good investments, and I'm happy to say that they're starting to show some very good results, for example, with sales in terms of the order book or DLM in terms of the number of DLM contracts that we are bidding and that we have won. As we continue to focus on growth, our focus firmly remains profitable growth, operating leverage, and sustainable improvement in margins, medium to long term. Looking ahead, we remain excited about the opportunities across our market sectors. Rising electronic content, growing AI infrastructure demand, global supply chain diversification, increasing investments across our focus sectors, and broader outsourcing trends continue to create a very strong, differentiated design-led manufacturing. The model, which is unique to Cyan DLM, our strong customer relationships, expanding execution capabilities, we believe Cyan DLM is well-positioned to capitalize on these opportunities. Most importantly, our H1 FY27 performance reflects a strong rebound over FY26, with revenue growth of more than 30%. It is supported by a record order book and a robust business pipeline, which provides greater visibility as we step into the second half of the year. I am confident that we will see this sustaining through the rest of the year and into next year. With a strengthened leadership team, improving growth momentum, and continued investments in our capabilities and growth areas, we remain confident in our ability to build a strong and more scalable business, create sustainable long-term value for our customers. We'll take you through the brisness and operating highlights.

So, good afternoon, everyone, and just thank you for joining SIGN-DLM's Q2-FA27 Investor Call. So, I will outline the structural opportunities ahead and explain how our long-term strategy positions signed DLM to participate in some of the fastest-growing high-reliability segments of the global electronics product and manufacturing services market. Let me begin with the market backdrop. The global EMS industry is on a structural growth path, with the market expected to rise from approximately $650 billion today to about $1.1 trillion over the next few years. Within this market, the high-reliability EMS segment in which we operate represents an estimated opportunity of roughly $230 billion. This growth is particularly relevant to signed DLM because it is driven by sectors that require deep engineering expertise, complex manufacturing, stringent quality standards, resilient supply chains, and long product life cycles. These requirements closely align with our capabilities in design-led manufacturing and high-reliability electronics. And if you just further look at it, there are three structural tailwinds which are expanding SIGN-DLM's addressable market. The first tailwind is rising demand for AI and data center infrastructure. The second one is semiconductor capital equipment. And the third tailwind is robotics. And the growing electronics content in all these three areas. Again, as this backdrop, we estimate an addressable EMS opportunity of closely around $58 billion in AI and data center infrastructure. And for EMS providers, this creates a significant opportunity in AI data center, box build solutions, cables, and other cooling controls. For Cyan DLM, this is a natural adjacency where our capabilities in high-reliability manufacturing, systems integration, and power electronics can become increasingly relevant. So, if you can look at it, together, AI and data center infrastructure, semiconductor capital equipment, and robotics extend Cyan DLM's growth runway while remaining closely aligned with our core strengths. Against this backdrop, our long-term strategic pivot follows three phases. Strengthen, expand, and transform. So this deliberate progression builds on a proven foundation, extends our core capabilities into attractive adjacencies, and ultimately creates a stronger product and platform mode. Our first priority is to strengthen the business we have today. We are anchored in four core industries, aerospace and defense, medical, industrial, and automotive, focused in electric vehicles. These markets form our foundation and are supported by a proven core stack. The margin framework for this phase is approximately 9 to 11 percent. We are focused on deepening customer relationships, improving execution, scaling programs, and reinforcing the operational capabilities that have earned customer trust. This foundation provides the credibility and capability base for the next phase of growth. In the second phase, from FI27 through FI29, we plan to apply this proven stack to new sectors. The portfolio will expand from four industries to seven, adding robotics and AI data center as key growth areas and sharpening our focus on semiconductor capital equipment alongside with our existing core industries. Our approach is disciplined. Enter adjacencies where customer requirements align with our engineering, manufacturing, quality, and supply chain strength. As the business mix evolves and scale improves, the margin framework for this phase is approximately 11 to 13 percent. Expansion is therefore not only about accessing new revenue pools, but also about improving the quality and resilience of growth across a broader range of high reliability and markets. From FY30 onward, our ambition is to transform the business by building a differentiated product and platform mode. We expect to retain the benefits of a diversified seven-industry portfolio while adding new platforms and expanding our built-to-specification product. So here I would like to elaborate on built-to-specification products, a key strategic priority for us. So, we recently renamed this offering as electronic products to reflect the broader value we now provide across the product life cycle. Beyond manufacturing, our capabilities span product architecture, detailed engineering, embedded hardware, and software integration, prototyping, testing, qualification, industrialization, and transition to volume production. So, we are pursuing several multi-million dollar opportunities in this area, demonstrating both our capabilities and customer relevance. As these programs progress from development and qualification to scaled production, we expect them to generate significant sustained growth from FI30 onward. Given the strength of the pipeline, the long-term nature of these engagements, and their potential to deepen strategic customer relationships, electronic products will remain a priority for investment and execution. The margin framework for this phase is approximately from 13 to 18 percent, reflecting a growing contribution from products, platforms, and intellectual property-led differentiation. Our objective is to move progressively up the value chain while building on the execution discipline and customer trust established in our core EMS business. As we execute our long-term growth strategy, we remain focused on deliberate, forward-looking investments that strengthen our competitive position and expand our addressable market. Over the past several quarters, we have accelerated efforts to build capabilities that deepen our presence in high-potential areas. Our investment approach includes strengthening domain expertise, expanding customer engagement, enhancing engineering and manufacturing capabilities, and accelerating the development of differentiated products and solutions. Although these investments carry near-term costs, they are essential to building a stronger foundation for sustainable and profitable growth, as said the question earlier. Thank you. We believe these investments will strengthen our strategic position and market relevance, enabling us to participate meaningfully in some of the world's most attractive technology and industrial growth trends. Turning to the second quarter, our performance demonstrates both strong demand and continued execution. The art book reached an all-time high with a book-to-bill ratio of 1.6 times. This provides a solid foundation for future growth and reflects the relevance of our capabilities across both established and emerging markets. 26.5% year-on-year in Q2, supported by strong growth in aerospace and industrial together with the continued traction in defense and net tech. If you look at for H1, revenue group 30% year-on-year. At the same time, the product mix is shifting toward higher value integration. Box build revenue increased 86% year-on-year. This is strategically important because it reflects our progression beyond component-level manufacturing toward more integrated solutions. We also added three new logos in this quarter, strengthening the pipeline for future business. In parallel, we completed the integration of Altec Electronics and renamed the business as Sion DLM Electronics Inc. This expands our global footprint and enhances our ability to serve customers across geographies. Finally, we are investing in the next engines of growth as said earlier, AI and data center infrastructure, robotics, and semiconductor capital equipment will continue to strengthen our built-to-specification and electronics product capabilities. Together, these initiatives align near-term execution with the longer-term margin and portfolio transformation outlined earlier. To conclude, signed ALM is positioned at the intersection of a large and expanding EMS market, accelerating demand in high-reliability sectors, and a clear internal roadmap to move up the value chain. Our record order book, Strong Year-on-Year Revenue Growth, Improving Mix, New Customer Wins, and Broader Global Footprint demonstrates that this strategy is translating into operating momentum. We remain focused on disciplined execution, profitable growth, and building differentiated capabilities that can support sustainable margin and expansion over time. Thank you for your time and continued interest in signed DLF. Now, I hand it over to R.M. Subramanian, our CFO.

Thank you, Rajendra, for the business overview. Good evening, ladies and gentlemen. I will now take you through the financial performance for Q2 and H1 of FY27. Delivered a revenue of 3,931 million INR, representing a strong growth of 26.5% year-on-year, reflecting the continued momentum in the business. Our order book reached an all-time high of INR 28.1 billion, increasing by approximately Rs. 2.1 billion sequentially. This provides us with a healthy foundation for growth going forward. At the operating level, EBITDA for the quarter was Rs. 342 million, up 9.5% year-on-year, with an EBITDA margin of 8.7%. The margin is lower by 135 basis points year-on-year, Reflecting our continued investment in growth areas. Moving to profitability, normalized PATH grew 25.8% year-on-year to Rs. 158 million, broadly keeping pace with our revenue growth, while the normalized PATH margin remained stable at 4%. Reported PATH for the quarter was Rs. 340 million. The difference between the normalized and reported PATH reflects the one-time reversal of the earn-out provisions of Rs. 182 million. We see this as a quarter of strong growth with continued strengthening of the order book. Our focus going forward remains on converting this growth into a stronger operating performance and improving margin as the business scales. Now, let me provide some perspective on the trends across our key financial metrics. Starting with revenue, we have maintained a strong growth trajectory, the revenue reaching Rs. 3,931 million in Q2 FY27 compared with Rs. 3,106 million in Q2 last year, representing a growth of 26.5% year-on-year. On profitability, EBITDA for the quarter was Rs. 342 million, with an EBITDA margin of 8.7%. The moderation in margin reflects our continued investment in sales, strategy, and new growth areas to support the next phase of growth. Importantly, despite these investments, our underlying profitability remains healthy. As we look at the overall trend, we continue to see strong revenue momentum and healthy underlying earning growth while making the necessary investment to build cable Moving to the next set of KPIs, let me touch upon our order book and working capital performance. Our order book continued to strengthen and reach an all-time high of Rs. 28.1 billion at the end of Q2 FI 27 compared to Rs. 26 billion in the previous quarter. This gives us a healthy base as we move forward. On working capital, networking capital improved sequentially to 153 days from 161 days in Q1. Inventory days remained stable at 162 days, while DSO improved from 77 days to 73 days. DPO increased from 63 days to 68 days, providing further support to the working capital price. Customer advances stood at 13 days compared with 15 days in the previous quarter. Overall, the sequential improvement in working capital together with disciplined execution helped us generate an operating free cash flow of Rs. 172 million during the quarter. Going forward, working capital efficiency, particularly inventory optimization and collections will remain an important area of focus as we continue to scale the business. Let me now give you some perspective on our revenue mix for the quarter. From an industry standpoint, aerospace continues to be our largest segment, contributing 47% of our revenue, followed by industrial at 31%. These two segments delivered strong year-on-year growth of 62% and 29% respectively. Defense contributed 7% of our revenue with 13% year-on-year growth, while MedTech accounted for 14%, also growing 14% year-on-year. Looking at our product mix, PCBA continues to be the largest category at 48% of our revenue, growing 19% year-on-year. At the same time, we are seeing strong momentum in Voxville, which now contributes 37% of our revenue and grew 85% year-on-year. Geographically, our business continues to be predominantly international, with the rest of the world contributing 93% of revenue, and India's geography contributing 7%. The international mix continues to be supported by demand from aerospace, medical, and industrial customers. Overall, the revenue mix reflects strong growth across our key verticals, increasing contribution from box bill, and continuous strength in our international business. Let us now look at the detailed financial performance for the quarter. As mentioned earlier, revenue grew 26.5% year-on-year to Rs. 3,931 million, reflecting a strong growth momentum in the business. EBITDA stood at Rs.342 million, up 9.5% year-on-year, with an EBITDA margin of 8.7%, compared with 10% in the same quarter last year. The moderation in EBITDA margin was primarily driven by two factors. First, we saw an impact on the revenue mix and certain product development-related costs. Second, employee costs increased as we continue to invest in sales strategy and new growth areas to support the future growth. Below EBITDA, finance cost declined by 10.4% year-on-year to Rs. 61 million, supported by lower working capital borrowings. Reported profit before tax was Rs. 393 million and reported PAT was Rs. 340 million. It is important, however, to look at the profitability on a normalized basis. Other income during the quarter includes a one-time earn-out reversal of Rs. 182 million. Excluding this, our normalized PAD was Rs. 158 million, representing strong growth of 25.8% year-on-year, with a normalized PAD margin remaining stable at 4%. While we have seen some near-term impact of the EBITDA margin level, the underlying earnings growth remains healthy and broadly in line with our revenue growth. Our focus is remaining on sustaining growth while driving greater operational leverage and margin improvement as the business scales. As we complete our half-year through FI27, let me now summarize our performance for the first half of FI27. We delivered a revenue of Rs. 7669 million, representing growth of 30.2% year-on-year, supported by healthy business momentum and a strong order book. EBITDA for the first year was Rs. 733 million, growing 30.4% year-on-year, broadly in line with the revenue growth. Importantly, despite these investments we are making to strengthen our business, our EBITDA margin for H1 remains stable at 9.6%. At the bottom line, the performance has been particularly strong. Normalized path increased 60.4% year-on-year to Rs.321 million, with normalized path margin improving by 79 basis points to 4.2%. Reported path for H1 stood at Rs.503 million, up 27% year-on-year. The difference between reported and normalized path reflects the Rs.182 million one-time earned reversal recorded during the second quarter. Our order book stands at an all-time high of Rs.28.1 billion and increase of approximately Rs.5.2 billion compared with the same period last year, providing good visibility as we move into the second half. Overall, H1 reflects a strong and broad-based financial progress, with revenue and EBITDA growing around 30%, normalized earnings growing significantly faster, and the record order book supporting our growth trajectory. Since we have already covered most of the H1 performance highlights in the earlier dashboard, let me keep this slide brief and highlight just a few additional points. While the EBITDA margin remained broadly stable at 9.6%, we saw some impact from the revenue mix and product development-related costs, particularly in Q2. At the same time, we continue to make targeted investments in capabilities to support growth. Below EBITDA, finance costs declined by 21% year-on-year, supported by lower working capital borrowings. Overall, the underlying profitability remains strong, with normalized path growing at 60% year-on-year and normalized path margin improving by 79 basis points to 4.2%. To conclude, Q2 and H1 has been strong for us with a healthy revenue growth, a record order book, and strong growth in underlying profitability. As we enter H2, our focus will be on continued momentum in order intake, executing the order book, improving margins, and driving working capital efficiency as we continue to scale the business. We remain confident in the growth trajectory of the business and our ability to translate this growth into sustainable value creation. Thank you. Let's move to question and answer part now.

Operator

Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and 1 on their touchstone telephone. If you wish to withdraw yourself from the question queue, you may press star and 2. Participants are requested to please use handsets while asking a question. Ladies and gentlemen, we will now wait for a moment while the question queue assembles. Our first question comes from the line of Bala Subramanian with Arihant Capital. Please go ahead.

Bala Subramanian Analyst — Arihant Capital

Good evening, sir. Thank you so much for the opportunity. Sir, my first question, the margin impacted due to one-off revenue mix and product development spend, and how much it impacted in Q2, especially in product development spend, and what is the annual product development budget over the next two to three years, Yes, and whether we are capitalizing or whether we are expensive.

Yes, this is Subramanian here. In terms of the margin impact, we explain the reasons for that. I would like to clarify that it's a marginal investment in terms of what we have done, which is in the range of 100 to 150 basis points, and as a policy, today we are not capitalizing any of the cost what we are doing. Some of the costs are forward-looking in terms of employee We will not like to get into in terms of individually What is the product development spend? But that's part of our business, which Rajendra talked about in terms of electronics product division. So as we keep moving forward and as we identify opportunities, we will keep investing on a healthy basis. But we don't want to be putting a number in terms of what we'll be doing. This depends on the opportunities available in the market and what we'll be doing.

Bala Subramanian Analyst — Arihant Capital

Okay. As I mentioned, new growth engines like AA data center, semiconductor, and robotics, those areas. So, what are the work we are doing right now? How do you look at those growth engines next to maybe three to five years time frame? Especially, you mentioned post-F530, we have seen focus will be different.

Yeah, I think, as I said earlier, I think also, if you look at the new areas, the AI and data center infrastructure, robotics, and also on the semiconductor capital equipment, I think on the semiconductor capital equipment, we are already there. We are already working right now. And on the other two areas where I said earlier, so I think we just started exploring it right now, and it may take some time for us to get to a number there. So that's why I think we'll come back on where we stand on those things probably after by the end of this financial year.

Bala Subramanian Analyst — Arihant Capital

Okay, sir. Thank you.

Operator

Thank you. Our next question comes from the line of Santosh Seshadri with Aventus Park. Please go ahead.

Santosh Seshadri Analyst — Aventus Park

Yeah, hi. Good evening, sir. Thanks for taking up my question. So, I just want to follow up on the margin part of the question, folks. Could you help us quantify how much of this impact was due to one-off product development costs and how much due to underlying revenue exchange? And also, you know, just to get some flavor on what is driving the revenue exchange. So, basically, is it the shift between BTBA versus Foxborough or the BTS to BTP that you are talking about? And the second part of the question is, as you continue to grow the business, how should we think about, you know, the instances of all these product development costs occurring again?

So, what we are seeing is a mix of various factors in terms of revenue product mix. Some investments into the future in terms of the cost. So what we definitely see, this is leading to getting back to the margin levels of what we would like to get back into. And from a pure revenue product mix perspective, as you know, we are in a high mix, low volume business. And there will be a small amount of movement. It's not a static in terms of revenue mix. But as we keep moving forward, we are confident that, you know, in terms of overall margins, we should get back to what our targeted levels are.

Santosh Seshadri Analyst — Aventus Park

And, Justin, I'm sorry if I missed it earlier. What would be the margin guidance for FI27?

Yeah, FI27, as I said earlier, we will be at a high single-digit number, maybe close to around 9% EBITDA margin. Okay. And if you look at on the Q1, so whatever the investments you're making, whatever we are seeing in some of these one-offs which we have, I think from the Q1 onwards, we won't be having a double-digit TPP.

Santosh Seshadri Analyst — Aventus Park

Thank you. And just lastly, on the timeline for executing the order book, what would be the typical timeline to convert these order into revenues? And also, on some of your new programs, like semiconductor programs, when do you exactly expect this to contribute to your revenue? You know, is it sad to say that from third quarter or fourth quarter onwards, we should start to see some meaningful revenue? And also, if you could help us quantify the run rate from some of these new programs.

Yeah, I think if you look at the order book, what we have, it is usually from 18 to 24 months. That's what the range. Maybe very few will be there beyond that two years. But otherwise, mostly it is 18 to 24 months is our order book, what we have. And coming back on the semiconductor capital equipment, we have already started working on that. In the last two quarters, we have the revenues on that. Now, that's where probably we will be seeing some ramp-up going in that particular industry.

Santosh Seshadri Analyst — Aventus Park

All right, sir. Thank you very much. Thank you.

Operator

Thank you. Our next question comes from the line of Shashank Jha with SP Capital.

Operator

Please go ahead.

Operator

Shashank, your line has been unmuted. You may proceed with your question.

Shashank Jha Analyst — SP Capital

Yes, sir. My question regarding EBITDA model, so you told that it will be around 9% for S-27. Have I got it correctly?

Yes, more RMA in that range. Yeah, 9% to 10% range. So, we will be, that is what we have currently in the guidance, yes.

Shashank Jha Analyst — SP Capital

And, sir, like, your order book is growing fast, but your revenue is not growing at that rate. Is it just external factors or the order book deliverables are in some other areas, like after one year or something like that?

I mean, now, if you look at the challenges, what we have is, I mean, due to all the challenges in getting the materials, so that's where I think the challenge is in the materials right now. The order book, what we have is we have to go and release the purchase address if you have done it, so getting the materials, that's why it is taking the time. So that's why the 18 to 24 months is what I said, that's where we will be closing these existing order books.

Shashank Jha Analyst — SP Capital

And you told about the bid pipeline, which is exceeding $1 billion. So, what can we expect coming out converging with you?

I think, so that's what the conversion usually happens. Whatever the OI conversions we are seeing it now, that's what the conversions, the book to bill ratio of 1.6. Now, if you look at it, what we had in the last quarter, and this quarter is close to 600 crores plus, that's where probably you will be expecting it for the next two quarters too.

Shashank Jha Analyst — SP Capital

No, sir, I asked about something, like you have a green pipeline of $1 billion, you say. Out of that, what do you expect to win?

I mean, the percentage of the wins, you are asking it, that one?

Shashank Jha Analyst — SP Capital

Yes, yes.

So, usually it will be close to around, I mean, by that time, I mean, whenever it's close, if you look at our past history, it will be close to around 40% is what the win rate shows. So, based on that, some of the things are there in the initial stage, lead and qualification. So, probably once we put those things, we will be coming close to around 40% of the win ratio.

Shashank Jha Analyst — SP Capital

Okay, got it. And regarding a beta margin for FI28, are we going to have it in double digits?

Double digits for the, yes. For FI 28 onwards, it will be a double digit, and for this year, I said, it will be 9 to 10.

Shashank Jha Analyst — SP Capital

Okay, got it.

Operator

Thank you. Our next question comes from the line of Meeth Jain with Systematics Asset Management.

Operator

Please go ahead. Meeth, your line has been unmuted. You may proceed with your question.

Operator

As we are not receiving a response from the current participant, we will move to the next participant. And our next question comes from the line of Umang Gadda with Avena Investment Management. Please go ahead. Hello, am I audible? Yes, yes. You are audible, sir.

Umang Gadda Analyst — Avena Investment Management

Yeah, thank you. Thank you for the opportunity. Sorry to harp on the margins part again. We are expecting kind of a squeeze in margin of around 1% this year compared to 26. And you mentioned that it's due to the product development cost and revenue mix. So can you, I don't know, clarify a little bit in detail that specifically, is it because of some nature of services mix changing like PCB box build or some industry mix changing in revenue because of that the margin is getting squeezed out? If you can explain that in a little bit of detail, that would be helpful.

I think whatever earlier I said is for this quarter is where we just mentioned about that revenue mix. But if you look at it, when you ask about FA26 compared to FA27, the main reason for that reduction is basically coming from the investments what we are making into the sales and marketing. So that's what I said earlier. These are all the future investments which we are making for the future growth.

Krishna Bodanapu Chairman

So I think if I may just qualify that if you look at our gross margin or contribution margin, both of which are quality of business, they are higher. Actually, they're significantly higher in FI27 year-to-date than they're in FI26. So the quality, just to clarify, this quarter there was a bit of a revenue mix. But again, even this quarter, if you compare it to the same quarter last year, our contribution margin is still higher. It's not the revenue mix. Revenue mix is always going to be there. I think that was just mentioned as it was a this quarter thing. The reason why margins are really lower is two things. One is we've invested quite a bit in sales and marketing, all of which is now in the P&M, right, in the SG&A, S&M or G&A. So all of the value of sales and marketing is there, which is depressing the margins, obviously, a little bit. And we continue to invest in product development, which is not capitalized. Again, the product development piece also has been going on for a while. It's not that it is something that we only started this quarter. So it's really net-net, if I may just clarify, the reason for the drop in margins by about 100 bps or so is because all these sales and marketing costs have been accounted for. We will not add any more sales and marketing costs till we at least hit above, or at least net new, we won't add any more sales and marketing costs till we hit at least double our revenue on a quarterly basis. So that's just the issue. It's a point in time issue that, you know, there's fully loaded. We've added a number of salespeople. We've added a number of bid people. We've added a number of marketing costs, et cetera, including, you know, we added a chief growth officer in Rama, et cetera, et cetera. So, it's just that the full benefit of, there's zero absorption right now, because if you look at it last year, we would have done a similar revenue with none of that cost, which is almost 150, 200 basis point. So, I just want to clarify that it's not a one-off thing, it's not a con. Yes, there is, there was a bit of a one-off, but there's always going to be there. It's just the fact that we're investing in sales and marketing, and we're investing in product development.

Umang Gadda Analyst — Avena Investment Management

So, sir, if I mean, just if I extrapolate this thing, so when you say FI 28 onwards, we will have 11% kind of margin, which is from close to 9% that we're expecting this year. So, do you mean that the intensity of investments will get lower or the result and outcome is going to get higher because of that with the margin expansion will happen of around 200 basis points? So, this intensity of investments will get kind of lower from Q3 or Q4 onwards?

That's what I think I said with Krishna. Whatever has been done, sales and the marketing cost, that is already done now. There won't be any future investment in that area. And so, I think once the revenues grows in FA28, when you are seeing the growth for the FA28, whatever the growth we have currently, same growth will continue in FA28. I think with the growth coming in, with the absorption and all, so we'll be seeing the EBITDA much is going up.

Umang Gadda Analyst — Avena Investment Management

Understood. And so one last question, if I can ask. I mean, a couple of weeks back, there was an interview printed in the newspaper that, you know, we have a $1 billion order book, you know, executable for the next seven years, design-led order book. I genuinely didn't kind of quite understand what does that mean or where this is accounted. So, you know, if you can, you know, throw some light on this.

Okay, so that is the predominantly on our build to spec, which is nothing but the electronic product, which we are working out for some of the customer programs. There are four major programs which we are working right now. I think if you look at it, some of the works which we are doing it, we already have some of the contracts signed with the customers. By FI 30 is where we are told that that share will be seeing the revenue coming in from that. So all the four programs are really coming. Now currently close to a billion dollars, which are not there currently in our order book. So I think once we materialize it, that's what we will be seeing our order book going up at that time.

Umang Gadda Analyst — Avena Investment Management

Okay, so you are saying you have the visibility of the order book, but it is not translated to order book yet. It will come in the later side when it is materialized properly.

Exactly, exactly. But the contracts, we know that what are the volumes are going to be there, what is the value of the contracts going to be, that's where I said it is a billion dollar.

Umang Gadda Analyst — Avena Investment Management

So the business is, I mean, the stage where you are in the negotiations, the business is bound to come to you, if I'm understanding that correctly.

We are already working on those programs right now. Our electronic product team, they are already doing the designs. Some of the products have gone at the stage of testing at a customer location. Some of our internal testings are happening. So the programs will be in the production from FY30 onwards.

Umang Gadda Analyst — Avena Investment Management

Understood. Thank you for answering my questions. Thank you.

Thank you.

Operator

Thank you. Ladies and gentlemen, in order that the management is able to address questions from all participants in the queue, you are requested to please restrict yourselves to two questions only. If you have further questions, you may rejoin the queue. Our next question comes from the line of Nishita with Sapphire Capital. Please go ahead.

Nishita Analyst — Sapphire Capital

Yes. Hi. Thank you for taking my question. So you mentioned that we have a billion, one billion of order book pipeline. And our win ratio is 40%. So that means that we can get to around 400 million of orders. So, if you can specify the timeline of when can we accept these orders in, and have you also, like, included the $1 billion of B2S that you just mentioned in this order pipeline?

Yeah, I think not the entire $1 billion, what I said, and the PTS is not in that one. There is only a part of that, okay? But the rest of the things are the ones which we will be getting it when we complete the various stages of the exit pipelines. So it's a little difficult to say that when are we going to close the entire thing, because some will take slightly more time, and we are also seeing some of the things going up. I think if you look at it sometime back, we were close to around $1.4 billion. Now it is in the range what we said, I mean, just more than a billion dollars. Probably it will take some time to close those things. Close to around $400 to $500 million. I mean, $400 to $500 million is what we can make it as our order intake going forward.

Nishita Analyst — Sapphire Capital

So $400 to $500 million from the existing pipeline. When can you expect this to, like, inflow in our order book?

Krishna Bodanapu Chairman

The way I would look at it is the order balance sheet, right, it's at a point in time. It's not like a P&L which would be for a period. So this billion dollars or one and a half billion dollars roughly, which is the unweighted pipeline, which the 1.4 we talked about previously was also unweighted, so 1.5 which has increased, It's really a continuous moving thing because if we close, you know, next quarter, again, let's assume we'll close in the same range, 60, 70 million dollars. We'll also add another, you know, X hundred million dollars into the pipeline. So it's a constant addition. So you can't say that the order or the pipeline is for a period. It is at a point in time. So, it constantly keeps adding. So, it's not that, you know, once this billion-dollar pipeline or billion-and-a-half-dollar pipeline is converted, we're exhausted. There'll be new things that will constantly be coming. So, what you should really be looking for is, has the order backlog grown? Because that indicates your future growth. And, of course, has the pipeline grown? Because that indicates the feeder for the future order backlog.

Nishita Analyst — Sapphire Capital

Right, right. Okay, understood. And my last question would be on our revenue growth. So, in Q1, we had quite a good growth of 35%, and in Q2, compared to that, we've grown 26% only. So, like, why was the growth now, and can we expect a growth of around 30-35% for the whole year of 527?

Yeah, I think now probably, yes, you will be getting that much of the growth going forward, 35% growth. And for this quarter, it is lower for various reasons. Not that you will have everything because it's all depending upon the availability of the material and the challenges what we'll be having with it. And some of the things here, customer sides, there will be some delays. So that's why it will be varying the growth percentage. It won't be even exactly Maybe the quarter, but if you look at the H1, we are there at 30% revenue growth, and, yeah, if you look at the H2, we will definitely go in above 30% growth.

Nishita Analyst — Sapphire Capital

Okay, perfect. Thank you so much.

Operator

Thank you. Our next question comes from the line of Sumanth Kumar with Ilal Oswal. Please go ahead.

Operator

Sumanth Kumar, your line has been unmuted.

Operator

You may proceed with your question. The current participant seems to have dropped from the queue. We will proceed to the next participant. Our next question comes from the line of Aditya Pal with MSA Capital Partners. Please go ahead.

Aditya Pal Analyst — Masu Capital Partners

Yeah. Am I audible?

Operator

Yes, you are audible.

Aditya Pal Analyst — Masu Capital Partners

Yeah. Thank you so much. So, Kujee, you wanted to understand over the last couple of quarters, F526, Q3, and Q4, you had mentioned that B2S sales contribution should be in double digit in F527. And if I were to understand correctly, there are higher EBITDA margin products, which would take our overall EBITDA margin in FY27 higher, and if we are investing, say, for example, 150, 200 basis points, this higher EBITDA margin, higher gross margin product should actually neutralize it. So, I am not able to connect the dots, if you can help me understand these two points.

Built-to-spec division is where we are now renamed as a product division, electronic product division. So in terms of whatever investments we make and the product development life cycle, it's a slightly longer life cycle. So cost happens in one particular quarter, and then obviously you'll see the results getting out in the later quarter. So overall what we will see is we will continually invest for the long term, not only on built-to-spec prototypes, product developments, etc. And the impact and the benefits will accrue more in the future. So, what we have the option is to capitalize some of the cost, which we have chosen not to do it, because from a pure conservatism principle, we would like to expense it. Okay. That's what we've been doing. Okay. So, sort of matching principles may not work from that perspective. Okay. So, but we are clear that we are continuing to invest for the long term, and the benefits will accrue as we move forward.

Aditya Pal Analyst — Masu Capital Partners

Understood. Last question, which is a combination of our B2, the Electronic Product Division, and the Aerospace and Defense. So, Krishna earlier mentioned to a participant that the B2S will start transpiring from F530 onwards, but one of our large EBITOL customers, they've already received a lot of order book and they've already said that they will launch their product in 2028, 2027-2028. So that becomes a, because that's a nine-year contract, high-margin B2S product, that becomes a large revenue stream for us. The second part to aerospace and defense is on Honeywell. So Honeywell recently won a very large contract for the avionics suite from Indigo for 800 airbuses. Can I plausibly say that a large part of that should accrue to us for contract manufacturing?

Yeah, I think on the Honeywell side, as you said, it is basically the bill-to-print. Yeah. We are already working with them. We have just made several of the prototypes. They are right now in the testing phase, and some modifications, engineering changes are happening. That's where it has took some time to just bring it back into the serial production.

Shashank Jha Analyst — SP Capital

Okay.

And your other question on the EvoTol, yes, there is also part of that. As I said, the contracts have been signed, but it is not there in our order book. It comes once we complete the engineering design and then the prototype testing, everything is done. That's where it will happen. So whenever the production happens in FY29, that's where probably you'll be seeing the revenues coming in for us also from FY29.

Aditya Pal Analyst — Masu Capital Partners

Just one last question. So if I see the Attune product, the micro VCS product that we signed with Honeywell, which is where we'll be making the liquid loops. So, two prompt questions to this. One is because we'll be manufacturing liquid loops, and we'll be using a precision manufacturing facility. So, intuitively, there should be a higher margin product for us. And second is, can this become a lateral capability when we expand to robotics and AI data centers?

So, I think basically, the program, whatever you said, that is predominantly a box built with a lot of electronics involved in that one. Okay. And it is not for the liquid cooling, anything, because there is entirely a different module. That is, again, a built-to-print. It is not a built-to-specification. It is completely a built-to-print program, which we are doing for the customer.

Operator

Thank you. Our next question comes from the line of Karan Sanwal with Niveshai. Please go ahead.

Operator

Hello. Am I audible?

Operator

You are audible, sir.

Karan Sanwal Analyst — Nivesha

Great. So, sir, I wanted to understand which projects are we currently working on in the B2S segment, and for which clients, and, you know, how large can these projects be once they mature, maybe in 28, 29, or the FY30?

That's what I said earlier. The four programs which we are doing on the built-to-specification are a product design programs right now, electronic products. So, there are close to a billion dollar, and where few other things are contract signed, and few will be contract signed once it comes to a stage. The production, as I said, I think in the earlier, so FI 29, probably it may start. So, FI 30 onwards is where you will be seeing the full production happening and the ramp up in FI 30 onwards.

Karan Sanwal Analyst — Nivesha

So, this billion dollar is across how many years?

For a period of some 7 to 9 years. Some are the 7 years, some are the 9 years programs.

Karan Sanwal Analyst — Nivesha

Okay. And also, how is this Altec, you know, presence, health care, and sharing the export market? If you could talk about in detail, like how is the U.S. defense projects via this facility, maybe B2S, B2P, and what revenue and margin can we expect for this part of the business? I'm asking about the Altec division which we acquired and changed the name recently. So I wanted to understand like how does it help to, you know, in the export market and what revenue and scale up can we expect in this, in that company, via that company?

Yeah, I think for the business, as I said, we just renamed that as a sign DLM Electronics Inc. So that business is currently doing as per our plans, and now I think there is a plan where we are working out, and there are the people, the sales team on the ground, who are looking for more of the growth coming in that area. So probably you will be seeing some more traction on the revenue in that division there in U.S.

Karan Sanwal Analyst — Nivesha

One last question. Currently, our revenue mix is towards the export market. So, I wanted to understand the B2S opportunity that we are working on plus the upcoming B2P opportunity. Would the revenue mix stay in the similar lines or would it change towards any of the market?

The revenue mix between build-to-print and build-to-spec.

Karan Sanwal Analyst — Nivesha

The geographies I'm asking about. Currently it's export-oriented. So would it change towards the domestic market happen, or would it continue to stay towards the export market only, the overall company revenue?

I think the export market will continue, but at the same time, there are also opportunities if you are working on the domestic market for some of the products for the built-to-spec. So we will be seeing a little growth in that India market, but otherwise the export market continues.

Karan Sanwal Analyst — Nivesha

Great. Thank you very much, and all the rest.

Operator

Thank you. Ladies and gentlemen, we will now take one last question, which will be from the line of Gaurav Shukla from Pinvestor. Please go ahead. I am audible, sir. You are audible, sir.

Gaurav Shukla Analyst — Pinvestor

Sir, as you said that your order book is 28.1 billion, current order book, then, sir, how much order book is executed in FY27? And how much in FY28?

Well, the order book, as Rajendra explained to it, in terms of having an average execution period of 18 to 24 months, Each of the contracts or the orders depends on various customers. Some of them give for 3 or 6 months, some of them for 12 months. So, it varies across. So, you know, we don't have the number in between individually. We don't publish the numbers of what is for each year. But I think it's good to say that the overall average execution period is anywhere between 18 to 24 months.

Gaurav Shukla Analyst — Pinvestor

Okay, sir. And, sir, what concrete customer engagement of products and programs are progressing in India?

I think for the semiconductor capital equipment, as I said, we are already working out on that and probably you will be seeing the growth in that area. Now onwards, you will be seeing the growth every quarter in that area. And on the AI data center and on the robotics, as I said, we just started exploring those two distinct sectors, which probably we have to wait till the end of the year, so that probably we'll come back and share more of the news at that time, where we stand and what opportunities we have and what pipeline we have in those areas.

Gaurav Shukla Analyst — Pinvestor

Okay, thank you, sir. Sir, one more, sir. In last Q2, there is other income of 23 crore, and in this Q2, also there is other income of 23 crore. So, then we should understand that in Q2, there will be other income or this is one-off?

Other income, this time, obviously, it's a mix of a couple of things. Okay, there are forex variations, which also contributes other income, and a few other one-off items in terms of some export incentives are also part of it. Okay, so every quarter it keeps varying.

Gaurav Shukla Analyst — Pinvestor

Okay, thank you, sir. All the best and good set of results. Thank you.

Operator

Thank you. I would now like to hand the conference over to Mr. Krishna Bodhanapu for closing comments. Over to you, sir.

Krishna Bodanapu Chairman

Thank you very much, and thank you, everybody, for participating this evening. As we said, we're very confident on where the business is headed. Backlog is strong. We're converting that to revenue. Yeah, there was a little bit of a hiccup with margin for the reason that we said. It's just that we consciously invested in both product development, which, as RMS clarified, is not capitalized. It's completely in the P&L, so there's no surprises in the future. And it's a full sales team that is now operating. So if nothing, just as we execute the revenue from the backlog into FI28, that itself will take our margins into 10 plus percent. That's without even doing any further additional effort. And the sales team, I'm very happy to say, the signs are very good. I mean, not just early signs. I think we're ready to convert some large orders from the new sales team, especially in the areas that Rajendra also talked about. So if I put all this together, I think we're in a great spot. I think we're over some of the challenges that we had. We're over all the challenges that we had last year. We're in a great spot, even if we just execute in steady state, which is absolutely not our intent. Our intent is to really increase the operational excellence and the conversion. But even in steady state, we're in a great shape. So I'm very excited about the business. Thank you for the support, and we will speak either during the course of the quarter, but definitely at the end of the quarter. Thank you.

Operator

Thank you. On behalf of Scient DLM Limited, that concludes this conference. Thank you all for joining us. You may now disconnect your lines.

Analyst Q&A · 10 questions
Full-screen source Call document